Rationale: Transplantation of human CD34 ؉ stem cells to ischemic tissues has been associated with reduced angina, improved exercise time, and reduced amputation rates in phase 2 clinical trials and has been shown to induce neovascularization in preclinical models. Previous studies have suggested that paracrine factors secreted by these proangiogenic cells are responsible, at least in part, for the angiogenic effects induced by CD34 ؉ cell transplantation.
C linical studies have provided evidence that locally transplanted autologous CD34 ϩ stem cells reduce angina and improve exercise capacity in patients with refractory angina 1 and lower amputation rates in patients with critical limb ischemia. 2 Preclinical studies indicate that the benefit of human CD34 ϩ cell transplantation after ischemic injury occurs through increases in neovascularization 3 ; however, the mechanisms of new blood vessel formation have not been completely characterized. Incorporation of CD34 ϩ cells into the growing vasculature has been documented in multiple studies 4 ; however, the magnitude of structural contribution of transplanted cells has typically seemed modest compared with the significant overall physiological impact. This dis-crepancy has led to the assumption that paracrine factors secreted by CD34 ϩ cells contribute significantly to the therapeutic angiogenesis induced by the cells. 5 Exosomes, a component of paracrine secretion, are extracellular, membrane-bound nano-vessicles that originate intracellularly in multivesicular bodies (MVBs) and are secreted out when the MVBs fuse with the plasma membrane. 6 They often carry proteins, RNAs, and/or microRNAs and mediate some aspects of cell-to-cell signaling. 6 We investigated the potential role of exosomes in CD34 ϩ cell-induced neovascularization by determining whether CD34 ϩ stem cells secrete exosomes, and, if so, whether these exosomes can induce angiogenic activity in the absence of CD34 ϩ cells.
Methods
All experimental protocols were approved by the Northwestern University Animal Care and Use Committee. Both CD34 ϩ cells 3 and CD34 ϩ cell-depleted mononuclear cells (MNCs) 3 were cultured, and exosomes from the conditioned media were obtained as described previously. 7 Electron microscopy, dynamic light scattering (DLS), flow cytometry, and immunoblotting analyses were performed according to established protocols. 7 The angiogenic activity of cultured human umbilical vein endothelial cells (HUVECs) was evaluated by means of the Matrigel tube-formation assay, proliferation was evaluated through 5-bromo-2-deoxyuridine incorporation, and viability was assessed by means of the MTS assay. In vivo angiogenesis was evaluated in nude (nu/J) mice by means of the Matrigel plug and corneal angiogenesis assays. Detailed methods are provided in the Online Supplemental Methods available at http://circres.ahajournals.org. Quantified results are presented as meanϮSD; comparisons between groups were evaluated with the Student t test; and PϽ0.05 was considered significant.
Results

CD34 ؉ Cells Secrete Exosomes
To investigate the role of exosomes in CD34 ϩ cell-induced neovascularization, we examined if the CD34 ϩ cells produce and secrete exosomes. Electron micrographs identified several MVBs in the cytoplasm of CD34 ϩ cells, carrying bilipidic membrane-bound exosome-like vesicles. The MVB membrane invaginated inward initiating the biogenesis of exosomes as previously shown 6 ; MVB fused to the plasma membrane and released the exosome-like vesicles to the media ( Figure 1A ). Because CD34 ϩ cells appear to be significantly more potent for inducing angiogenesis in ischemic tissue than unselected MNCs, 3 experiments were performed with exosomes isolated both from CD34 ϩ cells (CD34 ϩ exosomes) and from CD34 ϩ -depleted MNCs (MNC exosomes). Exosomes isolated from the conditioned media (CM) of both CD34 ϩ cells and MNCs were similar to previous descriptions of exosomes in size (40 to 90 nm in diameter), 7 cup-shaped morphology ( Figure 1B ), and in their unique flotation density (1.127 g/cm 3 , floated on 30% sucrose-D 2 O solution). DLS analysis confirmed the purity (100%) and mean hydrodynamic radius (CD34 ϩ : 50Ϯ7.8 nm;
MNC: 75Ϯ0.4 nm) of the exosomes in each preparation ( Figure 1C ). Exosomes from both CD34 ϩ cells and MNCs displayed the exosomal surface marker proteins CD63 and phosphatidylserine (Figure 2A and 2B) and contained the exosomal luminal protein TSG101 ( Figure 2C ). Further, CD34 protein was present on the surface of exosomes from CD34 ϩ cells but not on exosomes from MNCs ( Figure 2D ), which is consistent with previous reports that exosomes carry the same marker proteins that are specific for the secreting cell. 6 Collectively, these observations confirm that both CD34 ϩ cells and MNCs secrete exosomes and that the exosomes secreted by each cell population are biochemically distinct.
CD34 ؉ Exosomes Induce Angiogenic Activity in Endothelial Cells In Vitro
To determine whether CD34 ϩ exosomes induce angiogenic activity in vitro, tube formation was evaluated in HUVECs that had been cultured for 8 hours with PBS, CD34 ϩ cells, CD34 ϩ cell-CM, CD34 ϩ exosomes, or the exosome-depleted CM ( Figure 3A ). Tube length was significantly greater in HUVECs incubated with the CD34 ϩ cell-CM or with CD34 ϩ exosomes than in HUVECs incubated with PBS but was unchanged in HUVECs incubated with the exosome-depleted CM ( Figure 3B ). This suggests that CD34 ϩ exosomes mediate the in vitro angiogenic activity from the CD34 ϩ cell-CM. Interestingly, CD34 ϩ exosomes, similar to CD34 ϩ cells, induced longer-lasting tubes in HUVECs (Online Figure I) . Tube formation was less pronounced at lower exosome concentrations ( Figure 3C ). Both CD34 ϩ exosomes and CD34 ϩ cells significantly enhanced HUVEC viability (Figure 3D ) and proliferation ( Figure 3E ). Thus, most of the in vitro angiogenic activity associated with CD34 ϩ cells appears to be mediated by exosomes. HUVECs incubated with MNCs or MNC exosomes did not differ significantly from salinetreated cells in any functional parameter ( Figure 3D and 3E and Online Figures I and II) . The superior efficacy of CD34 ϩ exosomes compared with MNC exosomes is consistent with prior in vivo studies documenting the enhanced angiogenic activity of CD34 ϩ cells versus MNC for therapeutic angiogenesis. 3 Although the mechanisms that mediate the enhanced potency of CD34 ϩ cells versus MNC have not been completely clarified, preliminary data show that the proangiogenic microRNAs 126 and 130a 8 are highly expressed in CD34 ϩ exosomes compared with MNC (Online Figure III) .
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CD34 ؉ Exosomes Induce Angiogenesis In Vivo
The angiogenic potency of CD34 ϩ exosomes was evaluated in vivo by performing the Matrigel-plug and corneal angiogenesis assays in mice. Both CD34 ϩ cells and CD34 ϩ exosomes induced the formation of vessel-like endothelial structures (Figure 4A) and significantly increased the proportion of endothelial cells ( Figure 4B ) in the Matrigel plug. In the corneal angiogen-esis assay, pellets containing CD34 ϩ exosomes but not MNC exosomes were associated with significantly greater vessel growth ( Figure 4C and 4D) ; the effect of CD34 ϩ cells on corneal angiogenesis could not be evaluated because the pellets could not be prepared with viable cells.
Discussion
CD34 ϩ cells have been shown to form a structural component of the neovasculature in ischemic tissue 4 and secrete paracrine factors that also stimulate neovascularization. 5 We demonstrate that a significant component of the proangiogenic paracrine activity associated with CD34 ϩ cells is mediated by exosomes. The exosomes secreted by CD34 ϩ cells were morphologically similar in size and shape to exosomes described in previous reports, carried known exosomal protein markers, and potently induced angiogenic activity both in vitro and in vivo. The cell culture medium was supplemented with growth factors and may have contained soluble proteins secreted directly from the cells, which could, in principle, have contributed to the angiogenic effects associated with CD34 ϩ exosomes. However, the MNC exosomes were derived from MNCs cultured with the same growth factors, and the exosome-depleted conditioned media would have contained both the supplemental growth factors and any secreted soluble proteins. Because none of these treatments stimulated angiogenic activity, our findings indicate that the CD34 ϩ exosomes are the key paracrine component of CD34 ϩ cellinduced vessel growth.
Exosomes can stimulate both receptor-mediated and genetic mechanisms by transferring proteins, RNA, or microRNA directly into the cytoplasm of target cells. 9 We have presented data demonstrating that CD34 ϩ exosomes are enriched with proangiogenic microRNAs; the extent to which these microRNAs are transferred and induce any molecular changes in the recipient cells will be clarified in ongoing studies. Indeed, the repertoire of specific molecules transported by CD34 ϩ exosomes remains to be fully characterized, but they are likely to be more stable than molecules secreted directly into the extracellular matrix because the exosomal membrane protects the contents of the exosome from degradation. 6, 9 Furthermore, the exosomes used in our investigation were sufficiently durable to remain intact and biologically active throughout the isolation procedure, which suggests that the functional radius of CD34 ϩ exosomes could extend beyond the immediate vicinity of the secreting cell. The observation that in some of the in vitro and in vivo assays the exosomes from CD34 ϩ cells appeared more potent than the cells Figure 3 . In vitro assays. A, HUVECs (2.5ϫ10 4 ) were treated with PBS, 2.0ϫ10 4 CD34 ϩ cells, or with conditioned media (CM), exosomes (Exo), or exosomedepleted CM from 2.0ϫ10 4 CD34 ϩ cells and plated on Matrigel. B, Tube length was measured 8 hours later and expressed as percentage of saline-treated HUVECs (nϭ6 to 9). C, Representative dose-response of CD34 ϩ exosome tube formation, evaluated in HUVECs incubated with exosomes from 1.5ϫ10 5 CD34 ϩ cells and serially diluted with saline to the indicated ratios: D, viability, and E, proliferation of HUVECs (1ϫ10 4 ) in response to PBS, 2.5ϫ10 3 cells, or exosomes from 2.5ϫ10 3 cells, measured 20 hours later and expressed as percentage of PBS-treated HUVECs (nϭ3 to 6). *PϽ0.001 versus PBS, †PϽ0.05 versus Exo-depleted CM, ‡PϽ0.05 versus MNCs or MNC exosomes. Figure 4 . In vivo assays. A and B, Matrigel plug assay: Matrigel containing PBS, 5ϫ10 5 CD34 ϩ cells, or exosomes from 5ϫ10 5 CD34 ϩ cells was subcutaneously injected into mice, and the plugs were harvested 7 days later. A, Sections from the plug were stained with isolectin to identify endothelial cells (brown) and vessel-like endothelial structures (arrows). B, The plug was digested, and CD31 ϩ endothelial cells were quantified by flow cytometry (nϭ3 to 6). C and D, Corneal angiogenesis assay: Pellets containing PBS or exosomes from 1ϫ10 6 MNCs or CD34 ϩ cells were implanted in the corneas of mice; corneas were harvested 7 days later, stained with fluorescently labeled lectin identifying vascular structures (C), and the extent of vessel growth was quantified (D) (nϭ4). *PϽ0.05 versus PBS, ‡PϽ0.01 versus MNC exosomes. themselves is interesting and might also be a byproduct of the durability of the exosome in culture providing the ability to deliver a high dose of exosomes through collection from culture medium in which exosomes are secreted over a period of time.
In summary, our observations demonstrate for the first time that adult human CD34 ϩ stem cells secrete exosomes and that these exosomes induce angiogenic activity in isolated endothelial cells and in murine models of vessel growth. Thus, the benefit of CD34 ϩ cell therapy on functional recovery after ischemic injury could be induced primarily through the exosome-mediated transfer of angiogenic factors to surrounding cells. Novel therapies designed to exploit this previously unidentified mechanism of paracrine signaling may enhance recovery from ischemic disease or injury.
What New Information Does This Article Contribute?
• CD34 ϩ cells secrete exosomes that independently induce angiogenesis in vitro and in vivo. • The proangiogenic activity of CD34 ϩ exosomes is significantly greater than CD34-depleted mononuclear cell exosomes. • The exosomes from CD34 ϩ cells contain higher levels of proangiogenic microRNAs.
The clinical potential of CD34 ϩ cells for therapeutic neovascularization of ischemic tissue is being evaluated in a series of completed and ongoing clinical trials. Hence, the mechanisms by which CD34 ϩ cells mediate these effects are of high scientific and clinical importance. Although paracrine effects have been assumed to be responsible for a significant proportion of the effects of endothelial progenitor cell-based therapies in general, the precise nature of the paracrine phenomena has not been defined. Our data show that CD34 ϩ cells secrete exosomes that appear to be responsible for much if not most of their paracrine activity. Specifically, the conditioned medium from CD34 ϩ cells exerts proangiogenic effects that are abolished when the exosomes are removed, whereas the exosomes alone, without any of the soluble material from the conditioned medium, exhibit the full potency of the conditioned medium. Complete characterization of the exosome content of endothelial progenitor cells could provide new insights permitting enhancement of their therapeutic potency.
